Hepatotoxicity in patients co-infected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin

Objective: To evaluate the rate of and risk factors associated with hepatotoxicity in tuberculosis (TB) and human immunodeficiency virus type 1 (HIV-1) co-infected patients while receiving nonnucleoside reverse transcriptase inhibitors (NNRTI)-based antiretroviral therapy (ART) and rifampicin (RMP)-containing anti-TB regimens. Supplement: Abstracts of the Tenth International Congress on Drug Therapy in HIV Infection http://www.biomedcentral.com/content/pdf/1758-2652-13-S4-info.pdf Conference: Tenth International Congress on Drug Therapy in HIV Infection 7-11 November 2010 Glasgow, UK (Published: 8 November 2010) doi:10.1186/1758-2652-13-S4-P90 Cite this article as: Mankhatitham et al.: Hepatotoxicity in patients coinfected with HIV and tuberculosis while receiving NNRTI-based antiretroviral regimen and rifampicin. Journal of the International AIDS Society 2010 13(Suppl 4):P90. Full text: PubMed Central: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113098/